» Articles » PMID: 36950054

Diagnostic Work-up and Advancement in the Diagnosis of Gastroenteropancreatic Neuroendocrine Neoplasms

Overview
Journal Front Surg
Specialty General Surgery
Date 2023 Mar 23
PMID 36950054
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms ranging from well-differentiated, slowly growing tumors to poorly differentiated carcinomas. These tumors are generally characterized by indolent course and quite often absence of specific symptoms, thus eluding diagnosis until at an advanced stage. This underscores the importance of establishing a prompt and accurate diagnosis. The gold-standard remains histopathology. This should contain neuroendocrine-specific markers, such as chromogranin A; and also, an estimate of the proliferation by Ki-67 (or MIB-1), which is pivotal for treatment selection and prognostication. Initial work-up involves assessment of serum Chromogranin A and in selected patients gut peptide hormones. More recently, the measurement of multiple NEN-related transcripts, or the detection of circulating tumor cells enhanced our current diagnostic armamentarium and appears to supersede historical serum markers, such as Chromogranin A. Standard imaging procedures include cross-sectional imaging, either computed tomography or magnetic resonance, and are combined with somatostatin receptor scintigraphy. In particular, the advent of In-DTPA-octreotide and more recently PET/CT and Ga-DOTA-Octreotate scans revolutionized the diagnostic landscape of NENs. Likewise, FDG PET represents an invaluable asset in the management of high-grade neuroendocrine carcinomas. Lastly, endoscopy, either conventional, or more advanced modalities such as endoscopic ultrasound, capsule endoscopy and enteroscopy, are essential for the diagnosis and staging of gastroenteropancreatic neuroendocrine neoplasms and are routinely integrated in clinical practice. The complexity and variability of NENs necessitate the deep understanding of the current diagnostic strategies, which in turn assists in offering optimal patient-tailored treatment. The current review article presents the diagnostic work-up of GEP-NENs and all the recent advances in the field.

Citing Articles

NETest and Gastro-Entero-Pancreatic Neuroendocrine Tumors: Still Far from Routine Clinical Application? A Systematic Review.

Rossi R, La Salvia A Genes (Basel). 2025; 16(2).

PMID: 40004490 PMC: 11855739. DOI: 10.3390/genes16020161.


ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.

Ebner R, Sheikh G, Brendel M, Ricke J, Cyran C Eur Radiol. 2024; .

PMID: 39387873 DOI: 10.1007/s00330-024-11095-7.


The Investigation of B12 Deficiency Leading to the Serendipitous Diagnosis of Gastric Carcinoid Tumour.

Karam K, Saleh S, Chebbo H, Jalloul S, Fiani E Eur J Case Rep Intern Med. 2024; 11(8):004673.

PMID: 39130069 PMC: 11313110. DOI: 10.12890/2024_004673.


Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.

Franchina M, Cavalcoli F, Falco O, La Milia M, Elvevi A, Massironi S Diagnostics (Basel). 2024; 14(12).

PMID: 38928704 PMC: 11203125. DOI: 10.3390/diagnostics14121289.


Diagnostic Anatomic Imaging for Neuroendocrine Neoplasms: Maximizing Strengths and Mitigating Weaknesses.

Hesami M, Blake M, Anderson M, Asmundo L, Kilcoyne A, Najmi Z J Comput Assist Tomogr. 2024; 48(4):521-532.

PMID: 38657156 PMC: 11245376. DOI: 10.1097/RCT.0000000000001615.


References
1.
Lee L, Ito T, Jensen R . Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018; 18(9):837-860. PMC: 6283410. DOI: 10.1080/14737140.2018.1496822. View

2.
Mitra A, Mishra L, Li S . Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013; 31(6):347-54. PMC: 3665643. DOI: 10.1016/j.tibtech.2013.03.006. View

3.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

4.
Bodei L, Kidd M, Singh A, van der Zwan W, Severi S, Drozdov I . PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2019; 47(4):895-906. PMC: 7515632. DOI: 10.1007/s00259-019-04601-3. View

5.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View